BF
TEVA icon

BOK Financial’s Teva Pharmaceuticals TEVA Stock Holding History

BOK Financial’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,232
Closed -$36.3K – 1501
2024
Q2 		$36.3K Hold
2,232
– – ﹤0.01% 890
2024
Q1 		$31K Sell
2,232
-803
-26% -$10.1K ﹤0.01% 884
2023
Q4 		$31.7K Hold
3,035
– – ﹤0.01% 852
2023
Q3 		$26K Buy
3,035
+761
+33% +$7.09K ﹤0.01% 822
2023
Q2 		$17.1K Buy
2,274
+2,000
+730% +$16.2K ﹤0.01% 886
2023
Q1 		$2.42K Buy
+274
New +$2.71K ﹤0.01% 1104
2019
Q2 		– Sell
-12,114
Closed -$190K – 934
2019
Q1 		$190K Sell
12,114
-3,458
-22% -$61K ﹤0.01% 867
2018
Q4 		$240K Sell
15,572
-4,893
-24% -$100K 0.01% 782
2018
Q3 		$441K Sell
20,465
-945
-4% -$21.9K 0.01% 713
2018
Q2 		$520K Buy
21,410
+1,630
+8% +$33.2K 0.01% 657
2018
Q1 		$338K Sell
19,780
-21,025
-52% -$411K 0.01% 738
2017
Q4 		$773K Buy
40,805
+18,809
+86% +$283K 0.02% 550
2017
Q3 		$387K Buy
21,996
+2,158
+11% +$48.6K 0.01% 725
2017
Q2 		$659K Buy
19,838
+888
+5% +$27.5K 0.02% 562
2017
Q1 		$608K Sell
18,950
-1,415
-7% -$48.3K 0.02% 612
2016
Q4 		$739K Sell
20,365
-2,503
-11% -$99.9K 0.02% 540
2016
Q3 		$1.05M Buy
22,868
+521
+2% +$27.2K 0.03% 467
2016
Q2 		$1.12M Sell
22,347
-989
-4% -$52.7K 0.04% 421
2016
Q1 		$1.25M Sell
23,336
-6,559
-22% -$385K 0.05% 383
2015
Q4 		$1.96M Buy
29,895
+2,947
+11% +$182K 0.07% 307
2015
Q3 		$1.52M Sell
26,948
-24,035
-47% -$1.56M 0.06% 340
2015
Q2 		$3.01M Buy
50,983
+5,077
+11% +$313K 0.1% 232
2015
Q1 		$2.86M Buy
45,906
+11,450
+33% +$666K 0.1% 248
2014
Q4 		$1.98M Sell
34,456
-8,197
-19% -$457K 0.07% 298
2014
Q3 		$2.29M Buy
42,653
+659
+2% +$34.9K 0.08% 280
2014
Q2 		$2.2M Buy
41,994
+24,483
+140% +$1.25M 0.07% 298
2014
Q1 		$925K Sell
17,511
-214
-1% -$9.89K 0.03% 459
2013
Q4 		$710K Sell
17,725
-18,666
-51% -$735K 0.02% 524
2013
Q3 		$1.38M Sell
36,391
-212
-0.6% -$8.27K 0.05% 360
2013
Q2 		$1.43M Buy
+36,603
New +$1.43M 0.05% 329

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BOK Financial's TEVA Position: Q3 2024 in Review

BOK Financial sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 2,232 shares — an estimated $36.3K sold.

BOK Financial first reported a position in TEVA in Q2 2013 and held it in 30 quarters. The position peaked at $3.01M in Q2 2015. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • BOK Financial reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • BOK Financial sold 2,232 Teva Pharmaceuticals shares in Q3 2024, an estimated $36.3K.
  • BOK Financial first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 30 quarters.
  • BOK Financial's Teva Pharmaceuticals position peaked at $3.01M in Q2 2015.
  • 542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on BOK Financial's 13F filing for Q3 2024, filed 14 Nov 2024.